Carmen Bozic Sells 2,280 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total value of $1,089,840.00. Following the completion of the transaction, the chief marketing officer now directly owns 32,379 shares in the company, valued at $15,477,162. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Carmen Bozic also recently made the following trade(s):

• On Wednesday, May 29th, Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $445.56, for a total value of $1,015,876.80.

Vertex Pharmaceuticals Trading Up 0.4 %

NASDAQ:VRTX opened at $480.73 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $335.82 and a 12-month high of $486.42. The firm has a market capitalization of $124.05 billion, a P/E ratio of 31.20, a P/E/G ratio of 2.46 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The business has a 50 day simple moving average of $430.15 and a 200 day simple moving average of $418.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The business had revenue of $2.69 billion during the quarter, compared to analyst estimates of $2.58 billion. During the same quarter in the previous year, the firm posted $2.67 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sherbrooke Park Advisers LLC boosted its position in Vertex Pharmaceuticals by 65.3% during the 3rd quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock worth $920,000 after acquiring an additional 1,045 shares during the period. Telos Capital Management Inc. boosted its position in Vertex Pharmaceuticals by 1.6% during the 4th quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock worth $6,133,000 after acquiring an additional 237 shares during the period. Morgan Stanley boosted its position in Vertex Pharmaceuticals by 3.2% during the 3rd quarter. Morgan Stanley now owns 2,870,101 shares of the pharmaceutical company’s stock worth $998,050,000 after acquiring an additional 89,217 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Vertex Pharmaceuticals by 15.4% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 29,897 shares of the pharmaceutical company’s stock worth $12,497,000 after acquiring an additional 3,999 shares during the period. Finally, ARK Investment Management LLC boosted its position in Vertex Pharmaceuticals by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 124,197 shares of the pharmaceutical company’s stock worth $50,535,000 after acquiring an additional 8,866 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

VRTX has been the topic of several recent research reports. UBS Group reduced their price target on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. BMO Capital Markets boosted their price target on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, May 31st. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 7th. Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target on the stock in a research report on Thursday, April 11th. Finally, StockNews.com upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $438.48.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.